AND017 vs Molidustat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline
AND017
Developed by Kind Pharmaceuticals
NCT05265325 · Phase 2 · completed
The study was randomized, triple-blind, and active-controlled, with 175 participants assigned to AND017 or standard erythropoiesis-stimulating therapy. However, the registry does not report whether the primary endpoints—adverse-event incidence and mean hemoglobin change at Week 6—were met, so the findings cannot be judged as demonstrating a positive effect.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT07494409 (registry estimate)
No aligned efficacy figure on record for this race.
Molidustat
Marketed by Bayer
NCT03543657 · Phase 3 · completed
The trial randomized 229 participants to molidustat or darbepoetin alfa with matching placebos and quadruple blinding. Its primary endpoints were hemoglobin measures, which are laboratory surrogate outcomes. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
The mean Hb level during the evaluation period (From week 33 to 36); The change in mean Hb level during the evaluation period from baseline (Baseline and week 33 to 36): Mean Hb during evaluation period (weeks 33-36): molidustat 10.63 g/dL (95% CI 10.42-10.84) vs darbepoetin alfa 10.77 g/dL (95% CI 10.59-10.95); LS mean difference -0.13 g/dL (95% CI -0.46 to 0.19); noninferiority (margin 1.0 g/dL) established (met)
Result source: NCT03543657
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AND017 | Molidustat |
|---|---|---|
| Kidney composite outcome | —Trial running · NCT07487727 | —Not posted · NCT03350347 |
| UACR, % change | —Trial running · NCT07487727 | —Not posted · NCT03350347 |
| eGFR slope | —Trial running · NCT07487727 | —Not posted · NCT03350347 |
| Haemoglobin, change | —Trial running · NCT07487727 | —Not posted · NCT03350347 |
Kidney composite outcome
- AND017
- —Trial running · NCT07487727
- Molidustat
- —Not posted · NCT03350347
UACR, % change
- AND017
- —Trial running · NCT07487727
- Molidustat
- —Not posted · NCT03350347
eGFR slope
- AND017
- —Trial running · NCT07487727
- Molidustat
- —Not posted · NCT03350347
Haemoglobin, change
- AND017
- —Trial running · NCT07487727
- Molidustat
- —Not posted · NCT03350347
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AND017: no structured comparison results are available for Chronic Kidney Disease.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Molidustat
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AND017's landscape · Molidustat's landscape